Taiwan clinical trial hub for BioNTech mRNA-based cancer immunotherapies

16 December 2022

Announcing further plans to accelerate and broaden the clinical development of its cancer immunotherapy pipeline in the Asia-Pacific region, Germany’s BioNTech (Nasdaq: BNTX) said that the first regional clinical trial sites for the company’s mRNA-based cancer immunotherapies are planned to be activated in Taiwan to initially evaluate BioNTech’s cancer product candidate BNT113 against head and neck cancer.

Cash-rich due to the success of its Comirnaty COVID-19 vaccine developed with Pfizer (NYSE; PFE), BioNTech says BNT113 is expected to be the first product candidate from a potential wave of novel cancer immunotherapies that BioNTech anticipates to evaluate in the region.

These plans are part of BioNTech’s Asia-Pacific strategy, which has the aim of developing, manufacturing and broadening the access to innovative medicines in Asia, with a focus on treatments addressing the most common types of cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK